Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat + Lenalidomide + Dexamethasone in Multiple Myeloma
NCT01651039Phase 2Completed
- Start
- Jul 2012
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in multiple myeloma (MM). Primary endpoints: Best Overall Response Rate at 4 years and Overall Response Rate for Len Refractory Patients at 4 years. Started Jul 2012; status: completed.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01651039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01651039.